{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to continue their stable', 'dose of ICS alone or in combination with a second controller as used during the Screening', 'Period and instruct them to record daily usage in the electronic diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to withhold', 'bronchodilators according to their action duration, for example, withholding the last dose', 'of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding the', 'last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at', 'least 24 hours. This will be verified before performing the PEF measurements.', 'Schedule a site visit within a maximum of 35 days (Visit 2, Week 0) and request patient', 'and their parent(s)/caregiver(s)/legal guardian(s) to come at approximately the same time', 'of this visit.', '10.1.3 Randomization Visit 2 (Week 0, Day 1)', 'Reconfirm eligibility based on review of Inclusion/Exclusion Criteria.', 'Record all medication use with start date and dose in e-CRF; inquire about AEs/SAEs and', 'background asthma therapy tolerability.', 'Assess menstruation status and perform urine dipstick pregnancy test for female patients', 'who commenced menstruating, ie, are of childbearing potential', 'Administer ACQ-IA (ACQ-7) and assess if ACQ-5 score is >1.5', 'Administer all additional PROs:', 'PAQLQ(S)-IA, PRQLQ-IA, EQ-5D-Y for children, PACQLQ.', 'Administer HCRU', 'Compliance with use of the mandatory background therapy, ICS in combination with one', 'controller product as used just prior to screening, as defined as:', '-', '80% of total number of prescribed doses of background medication taken during the', 'Screening Period. Compliance is verified based on background medication use', 'recorded on the patient electronic diary during the Screening Period.', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of > 1 hour.', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight,', 'height)', 'Perform spirometry', 'Entry criteria at Visit 2 include the requirement of a specific FEV1 and demonstration of', 'reversibility as specified in Section 7.1 See below for additional directions.', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'Property of the Sanofi Group - strictly confidential', 'Page 80', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'the last dose of LAMA for at least 24 hours prior to administration of investigational', 'product. This will be verified before performing the PEF measurements.', '-', 'Pre-bronchodilator FEV1 must be 95% of predicted normal or pre-bronchodilator', 'FEV1/FVC ratio <0.85.', '-', 'Post-bronchodilator FEV1 should be determined.', 'Note: for patients that will have an additional and last attempt of reversibility testing', '(for eligibility) at the Baseline Visit 2, the post-bronchodilator FEV1 will come from', 'the result of this reversibility test.', '-', 'Patients must meet the inclusion criteria for spirometry at Visit 2 prior', 'to', \"randomization. If a patient's FEV1 does not qualify, then the patient will not be\", 'randomized.', '-', 'Treatment Period stability limits will be established for FEV1 and PEF (The Treatment', 'Period stability limit for PEF is defined as the respective mean AM or PM PEF', 'obtained over the last 7 days prior to Day 1).', 'If the patient meets all inclusion and does not meet any exclusion criteria:', 'Call IVRS/IWRS to register visit: Randomize the patient and receive the first assignment', 'for 1 treatment kit number.', '-', 'Note: If entry criteria are not met: Call IVRS/IWRS to register visit and Screen-fail the', 'patient.', 'Perform blood sampling (prior to administration of IMP) for the following tests:', 'Clinical laboratory testing: hematology/biochemistry (refer to Section 9.2.3.5)', '-', 'Systemic drug concentration and ADA (refer to Section 9.3.1)', '-', 'Obtain blood samples for total IgG, IgG subclasses -4, IgM and IgA.', '-', 'Biomarker set, total IgE, and antigen-specific IgE, and antigen-specific IgG4 panel', '(refer to Section 9.4.2.1)', 'Download electronic diary/PEF meter and remind patient/parent(s)/caregiver(s)/lega', 'guardian(s) to bring the device to the next visit.', 'Dispense and administer IMP', '-', 'For those parent(s)/caregiver(s)/legal guardian(s) who wish to learn and train to', 'home-administer the IMP injection (see Section 8.1.3 for details):', 'They will be trained by the Investigator or designee to administer IMP, by', 'demonstration at V2, V3, and V4 (injections performed by Investigator). The training', 'of parent(s)/caregiver(s)/legal guardian(s) for IMP injection is to be documented in the', \"patient's study file.\", 'Property of the Sanofi Group - strictly confidential', 'Page 81', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}